HDGabor, My point of view is influenced by the belief that what should have been a
very widely used, safe, and life saving medication was destroyed, at least in the US.
Why I say that any acquirer of AMRN should be Eurocentric is because that is where
the highest profit potential for the remaining exclusivity period for the drug is. My
fear is that AMRN management, without the distribution and reputation of a BP
that has a strong Cardiovascular distribution network in place, will sustain poor
uptake results. Amarin must compete against many over-the-counter products
so the reputation of the owner of Vascepa should be of paramount importance.
I commend you that you have been correct in predicting no takeover of AMRN.
We disagree on what I believe is the need of a BP owner to get Vazkepa to
as many Cardiovascular disease patients as practical. I do not believe that
Amarin by itself has the "gravitas" to get the job done. (Just my opinion.)
News 
Market Data 
Discover 
